|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2007091066A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Ucl Business Plc |
Applications of non-integrating lentiviral vectors
|
|
PL2020444T3
(pl)
*
|
2007-08-03 |
2017-10-31 |
Pasteur Institut |
Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek
|
|
DK2185192T3
(en)
|
2007-08-03 |
2019-02-18 |
Pasteur Institut |
LENTIVIRAL TRANSFER VECTORS AND THEIR MEDICAL USES
|
|
AU2013203416B2
(en)
*
|
2007-08-03 |
2016-10-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
EP2205752B1
(en)
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted integration
|
|
WO2009120947A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Virxsys Corporation |
Lentivirus-based immunogenic vectors
|
|
WO2009131706A1
(en)
*
|
2008-04-26 |
2009-10-29 |
Yung-Nien Chang |
Site-specific-integration lentiviral vectors
|
|
RU2012140691A
(ru)
*
|
2009-03-13 |
2014-03-27 |
Лентиген Корпорейшен |
Вакцины на основе неинтегрирующегося ретровирусного вектора
|
|
EP2419511B1
(en)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
EP2385107B1
(en)
|
2010-05-03 |
2016-08-24 |
Institut Pasteur |
Lentiviral vector based immunological compounds against malaria
|
|
WO2012152912A1
(en)
|
2011-05-12 |
2012-11-15 |
Newvectys |
Genetically modified pig as a cancer prone model
|
|
ES2651922T3
(es)
|
2011-11-08 |
2018-01-30 |
Institut Pasteur |
Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
|
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
|
WO2013149167A1
(en)
|
2012-03-30 |
2013-10-03 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
MX374532B
(es)
*
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
CN105683379A
(zh)
*
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
WO2015040063A1
(en)
*
|
2013-09-17 |
2015-03-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Lentiviral vectors having a mutated integrase protein and uses thereof
|
|
EP2878667A1
(en)
|
2013-11-29 |
2015-06-03 |
Institut Pasteur |
TAL effector means useful for partial or full deletion of DNA tandem repeats
|
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
ES2878449T3
(es)
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
EP3031923A1
(en)
*
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentiviral vector-based japanese encephalitis immunogenic composition
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
WO2017053707A1
(en)
|
2015-09-23 |
2017-03-30 |
Sensoriant, Inc. |
Method and system for using device states and user preferences to create user-friendly environments
|
|
WO2017060662A1
(en)
*
|
2015-10-07 |
2017-04-13 |
The Secretary Of State For Health |
Method for providing a control for use in a screen for pathogenic virus
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
WO2017214938A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
特异促进 bace1 基因高表达的慢病毒表达载体及应用
|
|
MA45996A
(fr)
|
2016-08-16 |
2021-06-02 |
Bluebird Bio Inc |
Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
|
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
KR102451510B1
(ko)
|
2016-09-08 |
2022-10-07 |
2세븐티 바이오, 인코포레이티드 |
Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
|
MA46543A
(fr)
|
2016-10-17 |
2019-08-21 |
Bluebird Bio Inc |
Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
|
|
WO2018085690A1
(en)
|
2016-11-04 |
2018-05-11 |
Bluebird Bio, Inc. |
Anti-bcma car t cell compositions
|
|
MA46862A
(fr)
|
2016-11-17 |
2019-09-25 |
Bluebird Bio Inc |
Convertisseur de signaux tgf béta
|
|
JP2020500562A
(ja)
*
|
2016-12-06 |
2020-01-16 |
ブルーバード バイオ， インコーポレイテッド |
ムコ多糖症ｉｉ型のための遺伝子治療
|
|
BR112019011635A2
(pt)
*
|
2016-12-06 |
2019-11-12 |
Bluebird Bio Inc |
terapia genética para mucopolissacaridose, tipo i
|
|
EP3357504A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
|
|
EP3357506A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
|
|
EP3583203B1
(en)
|
2017-02-15 |
2023-11-01 |
2seventy bio, Inc. |
Donor repair templates multiplex genome editing
|
|
MA48797A
(fr)
|
2017-05-25 |
2020-04-08 |
Bluebird Bio Inc |
Variants de l'endonucléase cblb , compositions et procédés d'utilisation
|
|
US11779654B2
(en)
|
2017-10-04 |
2023-10-10 |
2Seventy Bio, Inc. |
PCSK9 endonuclease variants, compositions, and methods of use
|
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
|
DK3806903T5
(da)
|
2018-06-14 |
2024-08-19 |
2Seventy Bio Inc |
Cd79a kimæriske antigenreceptorer
|
|
TW202019474A
(zh)
|
2018-07-11 |
2020-06-01 |
美商西建公司 |
抗bcma嵌合抗原受體之用途
|
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス， インコーポレイテッド |
ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
JP2022513750A
(ja)
|
2018-12-10 |
2022-02-09 |
２セブンティ バイオ インコーポレイテッド |
ホーミングエンドヌクレアーゼバリアント
|
|
IL283724B1
(en)
|
2018-12-10 |
2026-02-01 |
Genetix Biotherapeutics Inc |
pdcd-1 homing endonuclease variants
|
|
KR20210104772A
(ko)
|
2018-12-14 |
2021-08-25 |
블루버드 바이오, 인코포레이티드. |
이량체화제로 조절된 면역수용체 복합체
|
|
EP3947700A4
(en)
|
2019-04-01 |
2023-01-04 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
EP3770264A1
(en)
|
2019-07-22 |
2021-01-27 |
Genethon |
Precise integration using nuclease targeted idlv
|
|
EP4032907A4
(en)
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
Bcma-targeted antibody and chimeric antigen receptor
|
|
WO2021091978A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
WO2021094752A1
(en)
|
2019-11-12 |
2021-05-20 |
Oxford Biomedica (Uk) Limited |
Production system
|
|
EP4103723A1
(en)
|
2020-02-13 |
2022-12-21 |
Oxford BioMedica (UK) Limited |
Production of lentiviral vectors
|
|
WO2021181108A1
(en)
|
2020-03-13 |
2021-09-16 |
Oxford Biomedica (Uk) Limited |
Lentiviral vectors
|
|
WO2021212279A1
(zh)
*
|
2020-04-20 |
2021-10-28 |
广东东阳光药业有限公司 |
慢病毒的滴度提高型转移质粒
|
|
CN114807228B
(zh)
*
|
2020-04-27 |
2023-12-15 |
北京化工大学 |
一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
BR112023006305A2
(pt)
|
2020-10-09 |
2023-05-09 |
Tenaya Therapeutics Inc |
Métodos e composições de terapia gênica com placofilina-2
|
|
EP3984548A1
(en)
|
2020-10-16 |
2022-04-20 |
Institut Pasteur |
Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
|
|
EP4241278A2
(en)
|
2020-11-04 |
2023-09-13 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
EP4272002A1
(en)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
US20250319173A1
(en)
|
2021-03-12 |
2025-10-16 |
Institut Pasteur |
Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
|
|
JP2024517413A
(ja)
|
2021-04-16 |
2024-04-22 |
セルジーン コーポレーション |
以前に幹細胞移植を受けた患者におけるｔ細胞療法
|
|
JP2024525727A
(ja)
|
2021-07-14 |
2024-07-12 |
２セブンティ バイオ インコーポレイテッド |
抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
CN114181972A
(zh)
*
|
2021-11-23 |
2022-03-15 |
上海本导基因技术有限公司 |
适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
CA3255500A1
(en)
|
2022-04-08 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
|
|
WO2023198828A1
(en)
|
2022-04-13 |
2023-10-19 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
JP2025520227A
(ja)
|
2022-05-26 |
2025-07-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
レンチウイルスベクターを維持するための組成物及びその使用
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
EP4604993A2
(en)
|
2022-10-21 |
2025-08-27 |
Institut Pasteur |
Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
EP4688851A1
(en)
|
2023-03-27 |
2026-02-11 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025153530A1
(en)
|
2024-01-16 |
2025-07-24 |
Novo Nordisk A/S |
Albumin-targeted endonucleases, compositions, and methods of use
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|